Nippon India Pharma Fund Direct-Growth
NAV
₹572.5786
as on 05 Sep 2025, 11:12 PM
₹-2.4033(0.42%)
Last Change
Scheme Information
Nippon India Pharma Fund Direct-Growth
as of 31 Jul 2025, 05:30 AM
₹8,736.57 Cr
0.89%
0.55%
Open-End
Growth
Exit load of 1% if redeemed within 1 month.
BSE Healthcare Total Return Index
View
Sectors Holding in this Mutual Fund
Healthcare
99.45%
₹8,688.51 Cr
Cash Holding
0.55%
₹48.05 Cr
Healthcare
99.45%
₹8,688.51 Cr
Cash Holding
0.55%
₹48.05 Cr
Sun Pharmaceutical Industries Ltd.
12.57%
₹1,098.19 Cr
Divi's Laboratories Ltd.
9.49%
₹829.10 Cr
Lupin Ltd.
5.82%
₹508.47 Cr
Cipla Ltd.
5.62%
₹490.99 Cr
Dr. Reddy's Laboratories Ltd.
5.49%
₹479.64 Cr
Others
61.01%
₹5,330.18 Cr
Sun Pharmaceutical Industries Ltd.
12.57%
₹1,098.19 Cr
Divi's Laboratories Ltd.
9.49%
₹829.10 Cr
Lupin Ltd.
5.82%
₹508.47 Cr
Cipla Ltd.
5.62%
₹490.99 Cr
Dr. Reddy's Laboratories Ltd.
5.49%
₹479.64 Cr
Others
61.01%
₹5,330.18 Cr
Funds in this Category
This fund's returns: 24.22%
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
Min. Investment
₹100
29.35
Category Returns
19.81%
29.35%
3Y Returns
29.35 %
SBI Healthcare Opportunities Fund Direct Plan-Growth
Min. Investment
₹500
27.99
Category Returns
19.81%
29.35%
3Y Returns
27.99 %
UTI Healthcare Fund Direct-Growth
Min. Investment
₹500
26.97
Category Returns
19.81%
29.35%
3Y Returns
26.97 %
About Nippon India Pharma Fund Direct-Growth
Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is -0.73%, in last 3 years is 91.80% and 719.55% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
AUM: | ₹8,736.57 Cr |
Category: | Equity: Sectoral-Pharma |
Launch Date: | Invalid date |
Fund Type: | Open-End |
AMC Information
Nippon India Mutual Fund
Address
Investment Performance
₹ 1,00,000
would have given a return of
₹1,10,871
₹1,21,647
₹1,86,730
₹1,91,804
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
Profit (absolute return)
₹91,804
91.80%
Investment Returns
Scheme Riskometer
Investors understand that their principal will be at very high risk